Stay updated with breaking news from Release Tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction AUSTEDO is the... | June 10, 2023
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets The U.S. Food and Drug Administration ... | April 11, 2023
New once-daily AUSTEDO XR regimen now approved in 6, 12, and 24 mg tablet strengthsAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD) indications1,2AUSTEDO is the only VMAT2 inhibitor with 3-year long-...
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application Nifedipine Extended-Release Tablets USP, 30 mg, 60 mg and 90 mg.